Our Mission
Pioneering a New Era of GPCR Drug Discovery
The Opportunity
Unlocking the full potential of G protein-coupled receptor (GPCR) drug targets creates the opportunity to develop the next generation of impactful new medicines for patients across therapeutic areas
What we do
Powered by our proprietary, industrial-scale Native Complex Platform™, we are discovering new ways to drug GPCRs
Our industrial-scale platform aims to unlock previously difficult-to-drug GPCRs and has led to the discovery, optimization, and development of our pipeline of oral small molecule drug candidates.
Pipeline
Septerna is a clinical-stage biotechnology company with a deep pipeline of oral small molecule GPCR drug candidates and discovery programs
We are advancing a wholly-owned pipeline focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
About Us
World-class team of drug hunters, GPCR experts, drug developers, and company builders
We are a strong, values-driven organization aimed at advancing cutting-edge science and relentlessly focused on developing a portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches for patients with significant unmet needs.
Press Releases
Latest News
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering...
Septerna Prices Upsized Initial Public Offering
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering...
Septerna Presents New Preclinical Data at ASBMR 2024 Highlighting Therapeutic Potential of Oral Small Molecule Parathyroid Hormone 1 Receptor (PTH1R) Agonists for Hypoparathyroidism
In addition to maintaining serum calcium control, PTH1R agonists upregulated bone turnover ...
Septerna Announces Initiation of Phase 1 Clinical Trial with SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Trial Initiation Marks Septerna’s Transition to a Clinical-Stage Company Developing a Portfolio of...